Takeda Pharmaceuticals: Global Homepage

Drones, robots and digital apps yield promising results for patients in Japan

We exist to create better health for people and a brighter future for the world. While the science and technology we advance are constantly evolving, our ambition remains. We move science forward, so we can transform more lives.

Recent News

Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress

May 26, 2023

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

May 25, 2023

U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

May 17, 2023

Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2023

May 11, 2023

View All

Better Health, Brighter Future

Join Us

Work with globally diverse colleagues who are committed to bringing Better Health to people and a Brighter Future to the world.

FIND OUT MORE

Investors

Discover our balanced, diverse portfolio and strategy for sustainable, patient-centered and resilient growth.

FIND OUT MORE

R&D

Fueled by our inherent curiosity, we translate science into highly innovative, life-transforming medicines.

FIND OUT MORE

Our Focus Areas

Gastrointestinal and Inflammation

Understanding and addressing life-limiting gastrointestinal and inflammatory diseases

Rare Diseases

Working to transform treatments in immunology, hematology, metabolic and lysosomal storage disorders

Plasma-Derived Therapies

Improving the lives of patients with rare and complex chronic diseases through innovation in plasma

Oncology

Aspiring to cure cancer, with inspiration from patients and innovation from everywhere

Neuroscience

Driving medical innovation for patients with neurological diseases

Vaccines

Addressing unmet global health needs through vaccine development against infectious diseases

Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

Sign up

Takeda Pharmaceuticals: Global Homepage

Drones, robots and digital apps yield promising results for patients in Japan

Recent News

Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2023

Better Health, Brighter Future

Join Us

Investors

R&D

Our Focus Areas

Gastrointestinal and Inflammation

Rare Diseases

Plasma-Derived Therapies

Oncology

Neuroscience

Vaccines

Sign up for investors newsletter